10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

生物科技行业面临挑战，10X Genomics Inc (TXG)股价跌至52周新低，触及11.89美元。根据 InvestingPro 数据显示，技术指标表明该股票已处于超卖区域，公司保持着4.9的健康流动比率。这一最新价格水平凸显了公司股价的急剧下跌，过去一年累计下跌75.65%。投资者正在应对行业整体压力和公司特定不利因素的双重影响，导致持续抛售，最终使公司股价创下新低。这个52周低点清晰地 ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...

10x Genomics, Inc. (NASDAQ:TXG – Get Free Report)’s stock price gapped down prior to trading on Thursday following a dissappointing earnings announcement. The stock had previously closed at $ ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

Citi analyst Patrick Donnelly lowered the firm’s price target on 10x Genomics (TXG) to $20 from $23 and keeps a Buy rating on the shares ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, ...